GemPharmatech Co

GemPharmatech Co Net Debt

The Net Debt of GemPharmatech Co (688046.SS) as of Oct 22, 2026 is 20.03 M CNY. In the previous year, Net Debt was -51.27 M CNY — a change of -139.06% (higher).

Net Debt

20.03 MCNY

YoY

-139.06%

Last updated:

Net Debt of GemPharmatech Co is 2021 20.03 M CNY. Net Debt of GemPharmatech Co was 2020 -51.27 M CNY. It decreases by -139.06% higher compared to the previous year.

The GemPharmatech Co Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
-51.27 M CNY
Jan 1, 2021
20.03 M CNY
The GemPharmatech Co Net Debt history
YEARNet DebtYoY
20.03 MCNY-139.06%
-51.27 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GemPharmatech Co Stock analysis

What does GemPharmatech Co do? GemPharmatech Co., Ltd. generates revenue through the research and development, manufacturing, and sale of experimental mouse models. The company utilizes gene-editing and other technologies to produce these models, which are primarily sold to satisfy experimental demands in gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental research areas. Customized model breeding, drug efficacy analysis, and model customization services are also key revenue streams, targeting institutions engaged in biomedical research and pharmaceutical development. The company's products and services are tailored for clients in the fields of gene function cognition, disease mechanisms analysis, and drug target discovery. These clients include research institutions and pharmaceutical companies requiring specialized mouse models for preclinical studies and drug development. The firm's focus on gene-editing technologies enables it to provide high-quality, customized solutions that meet specific research needs. GemPharmatech's business model centers on providing innovative solutions for experimental research through its proprietary gene-editing technologies. By offering both standard and customized mouse models alongside related services, the company addresses the growing demand for precise and efficient research tools in the pharmaceutical and biotechnology sectors. The firm's revenue streams are directly tied to the sale of these models and the provision of specialized services to clients in the biomedical research industry. GemPharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GemPharmatech Co stock

Net Debt of GemPharmatech Co is 20.03 M CNY in 2021.

Net Debt of GemPharmatech Co changed from -51.27 M CNY to 20.03 M CNY, representing a -139.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt GemPharmatech Co since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's GemPharmatech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GemPharmatech Co

All Key Metrics — GemPharmatech Co